Ménière's disease is a chronic inner ear disorder characterized by the classic triad of episodic vertigo (20 minutes to 12 hours), fluctuating sensorineural hearing loss, and tinnitus/aural fullness, associated with endolymphatic hydrops. [1-2] Prevalence is approximately 50–200 per 100,000 adults, with peak onset between ages 40–60 and a biphasic occurrence in the 20s and 60s. [1][3]
1. History
- Vertigo characterization: True rotational vertigo (not lightheadedness or presyncope); duration of each episode (must be 20 min–12 hours for definite MD); frequency of attacks (average 6–11/year) [1-2]
- Aural symptoms: Unilateral hearing loss (often low-frequency initially), tinnitus (ringing/buzzing), aural fullness — ask if these fluctuate and if they cluster with vertigo episodes [2][4]
- Timing and triggers: Spontaneous onset; ask about salt intake, caffeine, alcohol, stress, weather changes, sleep deprivation, and allergies as potential triggers [1][5]
- Associated symptoms: Nausea/vomiting during attacks, postural instability, drop attacks (Tumarkin crises — sudden falls without loss of consciousness) [1]
- Important negatives: No loss of consciousness (LOC is never a symptom of MD), no focal neurologic deficits, no headache/photophobia (suggests vestibular migraine), no otalgia/otorrhea [1]
2. Alarm Features
- Focal neurologic deficits (dysarthria, dysphagia, diplopia, limb weakness/ataxia) → posterior fossa stroke [1][3]
- Sudden persistent vertigo >24 hours with severe imbalance → consider stroke or labyrinthitis [1]
- Direction-changing nystagmus, vertical nystagmus, or skew deviation → central cause [6]
- Rapidly progressive unilateral hearing loss without fluctuation → vestibular schwannoma or sudden SNHL [1]
- New headache with vertigo in a young patient → vertebral artery dissection [3]
- Loss of consciousness → not MD; evaluate cardiac/neurologic causes [1]
- Drop attacks (Tumarkin crises) → may indicate advanced MD but also warrant exclusion of central pathology [1]
3. Medications
- Acute attack (vestibular suppressants — limited course only):
- Meclizine 25–50 mg PO q6h PRN
- Dimenhydrinate 50 mg PO/IV q6h PRN
- Diazepam 2–5 mg PO/IV (short-term only)
- Ondansetron 4–8 mg IV/ODT for nausea
- Promethazine 12.5–25 mg IV/IM/PR for severe nausea [1]
- Maintenance therapy (AAO-HNS: "option" level):
- Diuretics (hydrochlorothiazide/triamterene) [1-2]
- Betahistine 16–48 mg TID (not FDA-approved in the US; widely used internationally) [2]
- Refractory disease:
- Intratympanic dexamethasone [1][4]
- Intratympanic gentamicin (ablative — risk of hearing loss) [1]
- Medications to avoid: Chronic vestibular suppressants (impair central compensation); ototoxic medications (aminoglycosides systemically, loop diuretics at high doses) [1]
- Cautions: Diuretics require monitoring of electrolytes; benzodiazepines should be short-course only [1]
4. Diet
- Sodium restriction: <1,500–2,300 mg/day (conventional recommendation, though evidence is limited) [1][3]
- Caffeine reduction: May affect inner ear blood flow via vasoconstriction [7]
- Alcohol limitation: ≤1 drink/day; can worsen vasoconstriction and fluid balance [3][7]
- Adequate hydration: Consistent fluid intake; avoid large fluctuations
- Note: A Cochrane review found no high-quality evidence supporting dietary interventions, but these remain widely recommended as first-line, low-risk measures [5][7]
5. Review of Systems
- ENT: Hearing changes, tinnitus quality/laterality, ear fullness, otorrhea, otalgia
- Neurologic: Headache, visual changes, photophobia, phonophobia, focal weakness, numbness, dysarthria, dysphagia
- Cardiovascular: Palpitations, syncope, presyncope (to exclude cardiac causes of dizziness)
- Psychiatric: Anxiety, depression, panic attacks (high comorbidity with MD; stress is a recognized trigger) [5]
- Rheumatologic/Immunologic: Joint pain, rashes (autoimmune inner ear disease) [1]
6. Collateral History and Family History
- Familial MD is found in approximately 10% of cases, with autosomal dominant inheritance and incomplete penetrance [5][8]
- Ask about family members with hearing loss, vertigo, or diagnosed MD [8-9]
- Migraine history in the patient and family — strong association with MD and important for differentiating from vestibular migraine [1][9]
- Social context: Occupational impact (driving, operating machinery), fall risk, psychosocial distress [5]
7. Risk Factors
- Age 40–60 (peak incidence); biphasic peak also in 20s [1][3]
- Slight female predominance [5]
- Allergies/atopy — proposed association [10]
- Autoimmune disease — linked to immune-mediated inner ear pathology [2][9]
- Migraine — at least twice as likely in MD patients [9]
- Viral infections (proposed trigger) [2]
- Head trauma (may cause Ménière's syndrome) [5]
- High dietary sodium, caffeine, alcohol intake [7]
- Stress and sleep deprivation [5]
8. Differential Diagnosis
9. Past Medical History
- Prior episodes of vertigo, hearing loss, or tinnitus (pattern over time is key to diagnosis) [1]
- History of ear surgery, ear infections, or ear trauma
- Migraine or headache disorders [1]
- Autoimmune conditions (rheumatoid arthritis, lupus, thyroid disease) [2]
- Allergies/atopy [10]
- Cardiovascular risk factors (hypertension, diabetes, hyperlipidemia — relevant for stroke exclusion)
- Medication history: ototoxic drugs, chronic vestibular suppressants, diuretics, antihypertensives [1]
10. Physical Exam
- Vital signs: Blood pressure (orthostatic hypotension?), heart rate
- Otoscopy: Typically normal in MD; rule out middle ear effusion, cholesteatoma, TM perforation
- Hearing assessment: Bedside Weber (lateralizes to unaffected ear) and Rinne (air > bone bilaterally, consistent with SNHL); whispered voice test
- Nystagmus: During acute attack — unidirectional, horizontal nystagmus beating away from the affected ear; between attacks may be absent [3]
- HINTS exam (if acute vestibular syndrome presentation):
- Head Impulse Test: normal (no corrective saccade) in central causes; abnormal in peripheral
- Nystagmus: direction-fixed = peripheral; direction-changing = central
- Test of Skew: positive skew deviation = central [6]
- Gait and Romberg: Assess postural stability
- Cranial nerves: Full exam to exclude CPA tumor or brainstem pathology [1]
- Cerebellar exam: Finger-to-nose, heel-to-shin, rapid alternating movements
11. Lab Studies
- No specific lab test diagnoses MD. Labs are used to exclude mimics:
- CBC, BMP (electrolytes, glucose, renal function)
- TSH (thyroid dysfunction can cause dizziness)
- RPR/VDRL + FTA-ABS (otosyphilis) — especially if bilateral or atypical [1]
- ESR, CRP, ANA (if autoimmune inner ear disease suspected) [1]
- Lyme serology (in endemic areas) [1]
- Monitoring on diuretics: Electrolytes (K⁺, Na⁺, Cr) periodically
12. Imaging
- First-line: Audiogram is the essential initial test (strong recommendation per AAO-HNS) — typically shows low- to mid-frequency SNHL [1][4]
- MRI brain/IAC with and without contrast: Indicated for asymmetric SNHL to exclude vestibular schwannoma or other CPA pathology [1][12]
- CT temporal bone without contrast: May be appropriate to evaluate for superior semicircular canal dehiscence [12]
- MRI with gadolinium-enhanced 3D-FLAIR: Can demonstrate endolymphatic hydrops (research/specialty use; not routine) [14]
- When imaging is unnecessary: If classic bilateral symmetric hearing loss with typical episodic vertigo and no red flags, imaging may be deferred [12]
13. Special Tests
- Audiometry: Gold standard initial test; low-frequency SNHL pattern [1]
- Electrocochleography (ECoG): Elevated SP/AP ratio supports endolymphatic hydrops; optional/adjunctive [1][4]
- Videonystagmography (VNG) / Electronystagmography (ENG): Evaluates vestibular function; may show unilateral caloric weakness; not routinely required for diagnosis [1]
- HINTS exam: Critical bedside test in the ED to differentiate peripheral from central vertigo [6]
- Dix-Hallpike maneuver: To exclude BPPV [1]
- Vestibular evoked myogenic potentials (VEMPs): Adjunctive; may be abnormal in MD but not diagnostic
- Note: AAO-HNS recommends against routinely ordering vestibular function testing or ECoG to establish the diagnosis [1]
14. ECG
- Not a primary diagnostic tool for MD, but should be obtained in the ED when:
- Syncope or presyncope accompanies dizziness (to exclude arrhythmia)
- Drop attacks occur (rule out cardiac syncope vs. Tumarkin crises)
- Cardiovascular risk factors are present
- Dangerous patterns to recognize: Prolonged QTc, Brugada pattern, heart block, new atrial fibrillation — any of which may present as "dizziness" and mimic or coexist with vestibular pathology [3]
15. Assessment
- MD is a clinical diagnosis based on history; there is no gold-standard diagnostic test [1-2]
- Definite MD: ≥2 spontaneous vertigo episodes (20 min–12 hr) + audiometrically confirmed SNHL + fluctuating aural symptoms + no better alternative diagnosis [2]
- Probable MD: ≥2 episodes (20 min–24 hr) + fluctuating aural symptoms + no better alternative diagnosis (audiometry not required) [2]
- Disease is unilateral initially in most cases; up to 50% may develop bilateral disease over decades [4]
- Natural history: attacks cluster early, then typically decrease over ~8 years, but hearing loss is progressive [1][15]
- Complications: permanent SNHL, chronic imbalance, Tumarkin drop attacks, significant psychosocial disability [1][5]
16. Treatment Plan
Acute attack (ED management)
- IV access, cardiac monitor if indicated
- Vestibular suppressants: meclizine 25–50 mg PO or dimenhydrinate 50 mg IV; diazepam 2–5 mg IV for severe cases
- Antiemetics: ondansetron 4 mg IV; promethazine 12.5–25 mg IV/IM
- IV fluids if dehydrated from vomiting
- Dark, quiet room; minimize head movement [1]
Outpatient maintenance (stepwise approach per AAO-HNS): [1]
- Lifestyle/dietary modification: Low-sodium diet, reduce caffeine/alcohol, stress management, adequate sleep
- Oral pharmacotherapy (option): Diuretics (HCTZ/triamterene 37.5/25 mg daily) and/or betahistine (where available)
- Intratympanic steroids: For active disease not responsive to noninvasive treatment
- Intratympanic gentamicin: For refractory disease (ablative; risk of further hearing loss)
- Surgery: Endolymphatic sac decompression (hearing-sparing), vestibular nerve section, or labyrinthectomy (hearing-ablative, last resort) [1]
Adjunctive
- Vestibular rehabilitation/physical therapy for chronic imbalance (not during acute attacks) [1]
- Hearing aids and assistive technology counseling [1]
17. Disposition
- Discharge criteria: Symptoms improving/resolved, tolerating PO, able to ambulate safely, reliable follow-up arranged
- Observation/admission criteria:
- Intractable vomiting/dehydration
- Inability to ambulate safely (fall risk, especially elderly)
- Concern for central cause (abnormal HINTS, focal neuro deficits) — admit for MRI/neurology
- New-onset drop attacks requiring further evaluation
- Specialist consultation triggers:
- ENT/Otolaryngology referral for all new suspected MD [1]
- Neurology if central cause cannot be excluded
- Audiology for formal audiometric testing [1]
18. Follow Up / Return Precautions
- Follow-up timing: ENT within 2–4 weeks for new diagnosis; audiogram at initial evaluation and serially to track hearing [1]
- Return to ED immediately for:
- New focal neurologic symptoms (weakness, speech changes, vision loss, severe headache)
- Loss of consciousness
- Vertigo lasting >24 hours without improvement
- Inability to keep down fluids
- Sudden complete hearing loss
- Patient counseling:
- MD is chronic but manageable; attacks typically decrease over years [15]
- Avoid driving or operating heavy machinery during active vertigo
- Keep a symptom diary (triggers, duration, frequency) to guide management [1]
- Psychological support — anxiety and depression are common comorbidities [5]
- Expected course: Episodes cluster early in disease, then frequency decreases; hearing loss tends to be progressive; average disease stabilization ~8 years [1][15]
Images
References
1. Clinical Practice Guideline: Ménière's Disease. — Basura GJ, Adams ME, Monfared A, et al. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2020.
2. Systemic Pharmacological Interventions for Ménière's Disease. — Webster KE, Galbraith K, Harrington-Benton NA, et al. The Cochrane Database of Systematic Reviews. 2023.
3. Dizziness: Evaluation and Management. — Rogers TS, Noel MA, Garcia B. American Family Physician. 2023.
4. Meniere's Disease. — Sajjadi H, Paparella MM. Lancet. 2008.
5. Lifestyle and Dietary Interventions for Ménière's Disease. — Webster KE, George B, Lee A, et al. The Cochrane Database of Systematic Reviews. 2023.
6. Head Impulse, Nystagmus, and Test of Skew Examination for Diagnosing Central Causes of Acute Vestibular Syndrome. — Gottlieb M, Peksa GD, Carlson JN. The Cochrane Database of Systematic Reviews. 2023.
7. Restriction of Salt, Caffeine and Alcohol Intake for the Treatment of Ménière's Disease or Syndrome. — Hussain K, Murdin L, Schilder AG. The Cochrane Database of Systematic Reviews. 2018.
8. Types of Inheritance and Genes Associated With Familial Meniere Disease. — Parra-Perez AM, Lopez-Escamez JA. Journal of the Association for Research in Otolaryngology : JARO. 2023.
9. Pathogenesis and Etiology of Ménière Disease: A Scoping Review of a Century of Evidence. — Rizk HG, Mehta NK, Qureshi U, et al. JAMA Otolaryngology-- Head & Neck Surgery. 2022.
10. Ménière disease. — National Library of Medicine (MedlinePlus) 2017.
11. Vestibular Migraine or Meniere's Disease: A Diagnostic Dilemma. — Chen JY, Guo ZQ, Wang J, et al. Journal of Neurology. 2023.
12. ACR Appropriateness Criteria® Dizziness and Ataxia: 2023 Update. — Wang LL, Thompson TA, Shih RY, et al. Journal of the American College of Radiology : JACR. 2024.
13. Acute Vestibular Syndrome. — Hotson JR, Baloh RW. The New England Journal of Medicine. 1998.
14. MRI Can Help Differentiate Ménière's Disease From Other Menieriform Diseases. — Li J, Li L, Jin X, et al. Scientific Reports. 2023.
15. Approach to Ménière Disease Management. — Wu V, Sykes EA, Beyea MM, Simpson MTW, Beyea JA. Canadian Family Physician Medecin De Famille Canadien. 2019.